XNYS
STE
Market cap22bUSD
Oct 30, Last price
227.12USD
1D
-2.16%
1Q
-0.56%
Jan 2017
237.02%
IPO
200.78%
Name
STERIS plc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
Key people
Independent Chairman of the Board · since 2018
Daniel Carestio
President, Chief Executive Officer, Director · since 2021
Chief Financial Officer, Senior Vice President · since 2017
Mary Fraser
Chief Human Resource Officer, Senior Vice President · since 2022
Kenneth Kohler
Senior Vice President, General Manager - AST · since 2024
Cary Majors
Senior Vice President and President - Healthcare · since 2022
Karen Burton
Chief Accounting Officer, Vice President · since 2023
Julia Madsen
Senior Vice President and General Manager - Life Sciences · since 2024
Andrew Xilas
Senior Vice President, General Manager - Dental · since 2021
Renato Tamaro
Vice President, Corporate Treasurer · since 2017
John Zangerle
Senior Vice President, General Counsel, Company Secretary · since 2018
Esther Alegria
Independent Director · since 2023
Richard Breeden
Independent Director · since 2008
Independent Director · since 2005
Independent Director · since 2020
Independent Director · since 2021
Nirav Shah
Independent Director · since 2018
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||